Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Agreement underscores benefit of collaboration to accelerate review of new evidence-based treatment options for people with PTSD Submission of new drug application expected in the second half of 2023
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved London, UK and San Jose, US – May 2, 2023 COMPASS...
Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session Findings are consistent with previously published Phase 2 data 1 on the...
Results demonstrate a biological correlation between reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders Study sheds light on neurological...
Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023 No serious adverse events observed in the...